Congratulations to Andrew McCarthy and the Axo Longevity team on raising an oversubscribed $5M seed round.
Axo is building a preventive health membership designed to make deeper health insight more accessible. The platform combines 100+ biomarker blood tests, ongoing tracking, and personalized guidance across nutrition, sleep, movement, and supplements so members can better understand what is happening in their bodies over time.
The need is clear: most healthcare still operates reactively, and many consumers only get meaningful testing or interpretation after something has already gone wrong. Axo’s model gives members a more structured way to monitor their health, identify imbalances earlier, and make targeted changes with clearer data behind them.
The company has already expanded across multiple European markets and built a broad partner lab network, making the experience more convenient for members who want preventive testing without navigating the traditional healthcare system on their own. Axo’s annual membership includes recurring biomarker analysis and an expert-backed plan, with the company continuing to add capabilities like an AI health copilot and wearable integrations.
We invested in Axo because we believe preventive health will increasingly look like an ongoing membership, not a one-off check-up. As biomarker testing becomes more affordable and consumers become more comfortable using data to manage their health, companies that can combine access, interpretation, and behavior change in one product will be well positioned.
This new financing will help Axo expand into additional countries, grow its laboratory network, and continue building a product experience that makes preventive health practical, personalized, and more affordable. We’re excited to see Andrew and the team continue building toward a new standard for proactive health across Europe.
Read the full Business Wire announcement.
Interested in investing alongside Everywhere Ventures? Learn more about joining our investor community here.